BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$80.4M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$61.6M |
| 3 |
PG&E
PCG
|
+$54.8M |
| 4 |
Deere & Co
DE
|
+$53.1M |
| 5 |
iShares MSCI Japan ETF
EWJ
|
+$28.6M |
Top Sells
| 1 |
Citigroup
C
|
+$1.44B |
| 2 |
Apple
AAPL
|
+$1.03B |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
+$813M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$721M |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$651M |
Sector Composition
| 1 | Communication Services | 11.04% |
| 2 | Financials | 10.89% |
| 3 | Healthcare | 10.16% |
| 4 | Technology | 9.96% |
| 5 | Consumer Discretionary | 9.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2776
Novartis
NVS
$240B
| $70.9K | ﹤0.01% |
942
| – | – |
|
|
ENZ
2777
DELISTED
Enzo Biochem, Inc.
ENZ
| $70.8K | ﹤0.01% |
8,690
+4,707
| +118% | +$38.4K |
|
|
TCS
2778
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
| $70.5K | ﹤0.01% |
992
-443
| -31% | -$31.5K |
|
2779
Winmark
WINA
$1.74B
| $70.4K | ﹤0.01% |
544
+211
| +63% | +$27.3K |
|
2780
Sonida Senior Living
SNDA
$500M
| $70.2K | ﹤0.01% |
347
+57
| +20% | +$11.5K |
|
2781
Acacia Research
ACTG
$317M
| $70.2K | ﹤0.01% |
17,328
+6,296
| +57% | +$25.5K |
|
|
DSKE
2782
DELISTED
Daseke, Inc. Common Stock
DSKE
| $70.1K | ﹤0.01% |
4,907
+2,908
| +145% | +$41.6K |
|
|
PTVCB
2783
DELISTED
Protective Insurance Corporation Class B Common Stock
PTVCB
| $70.1K | ﹤0.01% |
2,926
+2,038
| +230% | +$48.8K |
|
2784
1-800-Flowers.com
FLWS
$343M
| $70K | ﹤0.01% |
6,543
+3,874
| +145% | +$41.5K |
|
2785
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $69.8K | ﹤0.01% |
7,936
+4,247
| +115% | +$37.4K |
|
|
KIN
2786
DELISTED
Kindred Biosciences, Inc.
KIN
| $69.8K | ﹤0.01% |
7,384
+3,677
| +99% | +$34.7K |
|
|
NXEO
2787
DELISTED
Nexeo Solutions, Inc. Common Stock
NXEO
| $69.8K | ﹤0.01% |
7,665
+5,102
| +199% | +$46.4K |
|
|
ZNGA
2788
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $69.6K | ﹤0.01% |
17,402
-20,675
| -54% | -$82.7K |
|
2789
AMES National
ATLO
$182M
| $69.5K | ﹤0.01% |
2,496
+1,765
| +241% | +$49.2K |
|
2790
Westlake Chemical Partners
WLKP
$763M
| $69.4K | ﹤0.01% |
2,780
+680
| +32% | +$17K |
|
|
TTPH
2791
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $69.2K | ﹤0.01% |
549
+374
| +214% | +$47.2K |
|
2792
Telkom Indonesia
TLK
$19B
| $69.1K | ﹤0.01% |
2,146
-4,256
| -66% | -$137K |
|
|
CVLY
2793
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $69K | ﹤0.01% |
2,764
+1,943
| +237% | +$48.5K |
|
2794
iShares 3-7 Year Treasury Bond ETF
IEI
$16.9B
| $68.9K | ﹤0.01% |
564
-185
| -25% | -$22.6K |
|
2795
Dorian LPG
LPG
$1.35B
| $68.6K | ﹤0.01% |
8,351
+6,108
| +272% | +$50.2K |
|
|
LAYN
2796
DELISTED
Layne Christensen Co
LAYN
| $68.6K | ﹤0.01% |
5,466
+3,775
| +223% | +$47.4K |
|
2797
Arq
ARQ
$306M
| $68.6K | ﹤0.01% |
7,098
-3,356
| -32% | -$32.4K |
|
|
ORBK
2798
DELISTED
Orbotech Ltd
ORBK
| $68.5K | ﹤0.01% |
1,364
| – | – |
|
|
MFSF
2799
DELISTED
MutualFirst Financial Inc
MFSF
| $68.4K | ﹤0.01% |
1,774
+1,284
| +262% | +$49.5K |
|
2800
Karyopharm Therapeutics
KPTI
$55.9M
| $68.4K | ﹤0.01% |
475
+185
| +64% | +$26.6K |
|